Middle dose tested hit the primary endpoint of the Phase II trial

AZ will take the programme forward into clinical development

Over half of patients treated with combination therapy were alive and relapse-free after five years

Industry body says in vitro diagnostics are vital to clearing the backlog of undiagnosed conditions

The deadline for entering the 2020 PharmaTimes Communications Awards, Sales Awards and Marketer of the Year competitions has […]

Employee safety is patient safety – this becomes clearer than ever during the Corona pandemic. It is not […]

World Evidence-based Healthcare Day takes place on 20 October

Lumevoq is designed to treat vision loss associated with Leber Hereditary Optic Neuropathy

Researchers found combination treatment showed promise against a range of cancer types

People with sleep condition could be at an increased risk of adverse outcomes from COVID-19